SG11202009036YA - Multivalent antibody - Google Patents

Multivalent antibody

Info

Publication number
SG11202009036YA
SG11202009036YA SG11202009036YA SG11202009036YA SG11202009036YA SG 11202009036Y A SG11202009036Y A SG 11202009036YA SG 11202009036Y A SG11202009036Y A SG 11202009036YA SG 11202009036Y A SG11202009036Y A SG 11202009036YA SG 11202009036Y A SG11202009036Y A SG 11202009036YA
Authority
SG
Singapore
Prior art keywords
multivalent antibody
multivalent
antibody
Prior art date
Application number
SG11202009036YA
Other languages
English (en)
Inventor
Kruif Cornelis Adriaan De
Linda Johanna Aleida Hendriks
Ton Logtenberg
Loo Pieter Fokko Van
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG11202009036YA publication Critical patent/SG11202009036YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202009036YA 2018-03-30 2019-03-29 Multivalent antibody SG11202009036YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862650467P 2018-03-30 2018-03-30
PCT/NL2019/050199 WO2019190327A2 (en) 2018-03-30 2019-03-29 Multivalent antibody

Publications (1)

Publication Number Publication Date
SG11202009036YA true SG11202009036YA (en) 2020-10-29

Family

ID=66349617

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009036YA SG11202009036YA (en) 2018-03-30 2019-03-29 Multivalent antibody

Country Status (17)

Country Link
US (3) US11952424B2 (de)
EP (1) EP3774885A2 (de)
JP (1) JP2021519610A (de)
KR (1) KR20200139189A (de)
CN (1) CN111936514A (de)
AR (1) AR115320A1 (de)
AU (2) AU2019243665B2 (de)
BR (1) BR112020019795A2 (de)
CA (1) CA3094318A1 (de)
EA (1) EA202091871A1 (de)
IL (1) IL277672A (de)
MA (1) MA52212A (de)
MX (1) MX2020010267A (de)
PH (1) PH12020551504A1 (de)
SG (1) SG11202009036YA (de)
TW (1) TW202003569A (de)
WO (1) WO2019190327A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010267A (es) 2018-03-30 2020-11-06 Merus Nv Anticuerpo multivalente.
WO2020141973A1 (en) 2018-12-31 2020-07-09 Merus N.V. Mixed binding domains
WO2020141974A1 (en) 2018-12-31 2020-07-09 Merus N.V. Truncated multivalent multimers
TW202039578A (zh) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3結合分子
CA3139402A1 (en) 2019-05-09 2020-11-12 Merus N.V. Variant domains for multimerizing proteins and separation thereof
CA3165605A1 (en) 2019-12-24 2021-07-01 Merus N.V. Tgf-beta-rii binding proteins
EP4097131A1 (de) * 2020-01-29 2022-12-07 Merus N.V. Mittel und verfahren zur modulierung von immunzelleneingriffseffekten
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
CN115666723A (zh) 2020-05-21 2023-01-31 美勒斯公司 用于生产ig样分子的方法和手段
US20240117030A1 (en) * 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
US20230383012A1 (en) * 2022-04-13 2023-11-30 Xencor, Inc. Antibodies that bind pd-l1, pd-l2, and/or cd28
WO2024144396A1 (en) 2022-12-27 2024-07-04 Merus N.V. Method for generating bispecific proteins
WO2024144400A1 (en) * 2022-12-30 2024-07-04 Merus N.V. Promiscuous cd3 binding molecules
CN117946245B (zh) * 2023-02-23 2024-08-02 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118120A1 (de) * 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
EP1272647B1 (de) * 2000-04-11 2014-11-12 Genentech, Inc. Multivalente antikörper und deren verwendung
AU2001270609A1 (en) * 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
CN1461344A (zh) * 2000-07-25 2003-12-10 免疫医疗公司 多价靶结合蛋白
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PL3456190T3 (pl) 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
KR20190069615A (ko) 2008-12-09 2019-06-19 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
RU2562163C2 (ru) 2009-05-20 2015-09-10 Новиммун С.А. Библиотеки синтетических полипептидов и способы получения вариантов полипептидов с естественным разнообразием
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
ES2542744T3 (es) 2009-12-17 2015-08-11 Novimmune Sa Bibliotecas de polipéptidos sintéticos y métodos para generar variantes polipeptídicas diversificadas de forma natural
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
EP2748197A2 (de) * 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Fc-bispezifische tandem-antikörper
JP6138813B2 (ja) 2011-11-28 2017-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗ｐｄ−ｌ１抗体及びその使用
NZ630568A (en) 2012-04-20 2017-06-30 Merus Nv Methods and means for the production of ch3 domain-comprising molecules
MX368507B (es) 2012-05-15 2019-10-07 Bristol Myers Squibb Co Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-ctla-4 en la manufactura de un medicamento para el tratamiento de cáncer.
WO2013181634A2 (en) 2012-05-31 2013-12-05 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
WO2014022540A1 (en) 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
LT2900694T (lt) 2012-09-27 2018-11-12 Merus N.V. Bispecifiniai igg antikūnai kaip t ląstelių aktyvatoriai
EP2953974B1 (de) 2013-02-05 2017-12-20 EngMab Sàrl Bispezifische antikörper gegen cd3 und bcma
RU2015140917A (ru) 2013-02-26 2017-04-03 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
EP2789630A1 (de) 2013-04-09 2014-10-15 EngMab AG Bispezifische Antikörper gegen CD3e und ROR1
BR112016015140A2 (pt) * 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
CA2941030A1 (en) 2014-02-28 2015-09-03 Merus N.V. Antibodies that bind egfr and erbb3
WO2015130173A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
EP3954703A3 (de) 2014-05-29 2022-05-18 MacroGenics, Inc. Trispezifische bindemoleküle und verfahren zur verwendung davon
EP2982692A1 (de) 2014-08-04 2016-02-10 EngMab AG Bispezifische Antikörper gegen CD3-Epsilon und BCMA
CA2963696A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
CA2963692A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
EP3023437A1 (de) 2014-11-20 2016-05-25 EngMab AG Bispezifische Antikörper gegen CD3epsilon und BCMA
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
US10336824B2 (en) 2015-03-13 2019-07-02 Cytomx Therapeutics, Inc. Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
MX2018000344A (es) * 2015-07-10 2018-03-14 Merus Nv Anticuerpo que se une a grupo de diferenciacion 3 (cd3) humano.
HUE048939T2 (hu) 2015-08-03 2020-09-28 Engmab Sarl Human B sejt érési antigén elleni monoklonális antitestek (BCMA)
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP7296728B2 (ja) * 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
WO2017162890A1 (en) 2016-03-25 2017-09-28 Biomunex Pharmaceuticals Binding molecules to cd38 and pd-l1
MX2018013038A (es) * 2016-04-27 2019-03-28 Pfizer Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
AU2017255970B2 (en) 2016-04-28 2024-06-27 Biomunex Pharmaceuticals Bispecific antibodies targeting EGFR and HER2
CA3038020A1 (en) * 2016-09-23 2018-03-29 Merus N.V. Bispecific binding molecules that bind cd137
CN110177805B (zh) 2016-10-19 2024-04-02 英温拉公司 抗体构建体
BR112019008426A2 (pt) 2016-11-02 2019-09-03 Engmab Sarl anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo
CN110650752A (zh) * 2017-03-31 2020-01-03 美勒斯公司 用于治疗具有NRG1融合基因的细胞的ErbB-2和ErbB3结合双特异性抗体
CA3058341A1 (en) * 2017-03-31 2018-10-04 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
MX2020000055A (es) * 2017-07-06 2020-08-06 Merus Nv Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3).
IL271833B2 (en) * 2017-07-06 2024-09-01 Merus Nv Antibodies that regulate biological activity expressed by a cell
BR112020000209A8 (pt) * 2017-07-06 2020-08-11 Merus Nv moléculas de ligação que modulam uma atividade biológica expressa por uma célula
US11773170B2 (en) * 2017-08-09 2023-10-03 Merus N.V. Antibodies that bind EGFR and cMET
CN111432838A (zh) * 2017-12-01 2020-07-17 美勒斯公司 使用双特异性抗体和il-15进行联合治疗
MX2020010267A (es) 2018-03-30 2020-11-06 Merus Nv Anticuerpo multivalente.
WO2020141973A1 (en) * 2018-12-31 2020-07-09 Merus N.V. Mixed binding domains
CA3139402A1 (en) * 2019-05-09 2020-11-12 Merus N.V. Variant domains for multimerizing proteins and separation thereof
AR120566A1 (es) * 2019-11-26 2022-02-23 Novartis Ag Receptores de antígeno quiméricos y sus usos
EP4097131A1 (de) * 2020-01-29 2022-12-07 Merus N.V. Mittel und verfahren zur modulierung von immunzelleneingriffseffekten

Also Published As

Publication number Publication date
EP3774885A2 (de) 2021-02-17
WO2019190327A3 (en) 2019-11-14
TW202003569A (zh) 2020-01-16
EA202091871A1 (ru) 2021-06-22
KR20200139189A (ko) 2020-12-11
AU2023222983A1 (en) 2023-09-21
PH12020551504A1 (en) 2021-09-13
MA52212A (fr) 2021-02-17
US20190352401A1 (en) 2019-11-21
CA3094318A1 (en) 2019-10-03
AR115320A1 (es) 2020-12-23
WO2019190327A8 (en) 2021-06-17
BR112020019795A2 (pt) 2021-01-05
AU2019243665A1 (en) 2020-10-08
JP2021519610A (ja) 2021-08-12
US20240352127A1 (en) 2024-10-24
US11952424B2 (en) 2024-04-09
US20240360217A1 (en) 2024-10-31
IL277672A (en) 2020-11-30
AU2019243665B2 (en) 2023-06-01
WO2019190327A2 (en) 2019-10-03
CN111936514A (zh) 2020-11-13
MX2020010267A (es) 2020-11-06

Similar Documents

Publication Publication Date Title
IL279321A (en) Anti-SIRPalpha antibody
IL277672A (en) Multivalent antibody
SG11202106214YA (en) Novel anti-ccr8 antibody
IL280780A (en) Anti-TIGIT antibodies
IL280013A (en) Anti-IL36R antibodies
IL267797A (en) Anti-gpc3 antibody
IL279352A (en) IL-11RA antibodies
IL278010A (en) Antibodies to galectin 10
IL277030A (en) Antibodies
GB202110263D0 (en) Anti-btla antibodies
ZA202101177B (en) Anti-btla antibody
GB201811368D0 (en) Antibody
GB201817172D0 (en) Antibody
IL281594A (en) Antibodies against KLRG1
IL273529A (en) Anti-PACAP antibody
ZA202108836B (en) Anti-epha4 antibody
EP4083211A4 (de) Anti-cdcp1-antikörper
GB201806084D0 (en) Antibodies
GB201919062D0 (en) Antibody
GB201813597D0 (en) Antibody
GB201809945D0 (en) Antibody
SG11202105718TA (en) Modified antibodies
GB201819952D0 (en) Antibodies
GB201912008D0 (en) Antibody
GB201817309D0 (en) Antibodies